Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | MTOR | P42345 | 1/20 | 0.67 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.67 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.67 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015791 | 1.00 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL399323 | 1.00 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4879682 | 1.00 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| Phosphoric Acid SCHEMBL3100818 | 0.95 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| Phosphoric Acid SCHEMBL1299876 | 0.95 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| Pyrophosphoric Acid SCHEMBL3100835 | 0.90 | LMNA (0.57) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL24337513 | 0.90 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14929500 | 0.90 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10015807 | 0.90 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| Triphosphate SCHEMBL31006154 | 0.88 | P2RY2 (0.55) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115581703-A | Compound gemcitabine composition and application thereof | 江苏集萃分子工程研究院有限公司 | 2023-01-10 | — | — | CN | claimed |
| EP-0787138-B1 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | IMMUNOMEDICS INC (US) | 2006-06-28 | — | — | EP | claimed |
| EP-0787138-A4 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | IMMUNOMEDICS INC (US) | 2000-03-08 | — | — | EP | claimed |
| US-5976492-A | Radioactive phosphorus labeled proteins for targeted radiotherapy | IMMUNOMEDICS, INC. (US) | 1999-11-02 | — | — | US | claimed |
| US-5728369-A | Radioactive phosphorus labeling of proteins for targeted radiotherapy | IMMUNOMEDICS, INC. (US) | 1998-03-17 | — | — | US | claimed |
| EP-0787138-A1 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | Immunomedics, Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1996011208-A1 | RADIOACTIVE PHOSPHOROUS LABELING OF PROTEINS FOR TARGETED RADIOTHERAPY | IMMUNOMEDICS, INC. (US) | 1996-04-18 | — | — | WO | claimed |
| JP-10330395-A | — | — | None | — | — | JP | disclosed |
| US-20240166675-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2024-05-23 | — | — | US | disclosed |
| EP-3851030-B1 | MEDICAL DEVICE FOR ANALYTE MONITORING | LABRADOR DIAGNOSTICS LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230034174-A1 | IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS, AND IMMUNOTOXINS | UNIVERSITY OF MIAMI | 2023-02-02 | — | — | US | disclosed |
| CN-115581703-A | Compound gemcitabine composition and application thereof | 江苏集萃分子工程研究院有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-11395846-B2 | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins | UNIVERSITY OF MIAMI (US) | 2022-07-26 | — | — | US | disclosed |
| EP-0882734-A2 | 5'-Deoxy-cytidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-09 | — | — | EP | disclosed |
| EP-0882734-A2 | 5'-Deoxy-cytidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-09 | — | — | EP | disclosed |
| EP-0882734-A2 | 5'-Deoxy-cytidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-09 | — | — | EP | disclosed |
| CN-1201037-A | 5'-deoxy-cytidine derivatives | HOFFMANN LA ROCHE (CH) | 1998-12-09 | — | — | CN | disclosed |
| CN-1201037-A | 5'-deoxy-cytidine derivatives | HOFFMANN LA ROCHE (CH) | 1998-12-09 | — | — | CN | disclosed |
| US-5728369-A | Radioactive phosphorus labeling of proteins for targeted radiotherapy | IMMUNOMEDICS, INC. (US) | 1998-03-17 | — | — | US | disclosed |
| US-4071680-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166675-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, NUDT1, NT5C3B | LMNA 3045/4885THRB 3628/4885MTOR 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.